Answers are grounded in this paper and cite their sources.
Introduction Mechanistic target of rapamycin (mTOR) signaling is both essential for renal cellular homeostasis and a driver of pathological remodeling when persistently activated. This paradox is especially evident in podocytes, where excessive mTOR complex 1 (mTORC1) activity promotes hypertrophy, metabolic stress, proteinuria, and fibrosis, whereas excessive suppression can destabilize the filtration barrier. Methods We review cell- and context-specific functions of mTORC1 and mTOR complex 2 (mTORC2) across kidney disease, including podocytopathies, chronic kidney disease, acute kidney injury-to-chronic kidney disease transition, and transplantation. Results We propose that the therapeutic objective should shift from global mTOR inhibition toward precision modulation defined by cell identity, molecular complex, dose, disease stage, and duration. Podocyte-targeted everolimus delivery provides preclinical support that spatial restriction can reshape pathway effects and raises the hypothesis that it could widen the therapeutic window. Discussion This homeostatic window theory may guide safer antifibrotic and glomerular therapies.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: